Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
$116.30
$115.72
$60.03
$116.38
$26.63B1.032.50 million shsN/A
Sysmex Co. stock logo
SSMXY
Sysmex
$16.11
+0.2%
$17.44
$15.02
$36.57
$10.14B0.6656,064 shs48,279 shs
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
$13.39
-2.5%
$15.31
$12.85
$30.41
$2.27B0.944.73 million shs4.07 million shs
Varian Medical Systems, Inc. stock logo
VAR
Varian Medical Systems
$177.07
$177.00
$103.67
$177.38
$16.26B1.06746,779 shsN/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
0.00%0.00%0.00%0.00%+5.17%
Sysmex Co. stock logo
SSMXY
Sysmex
+0.16%+2.64%-9.86%-9.59%-28.04%
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
-0.07%+4.57%-8.92%-32.54%-48.17%
Varian Medical Systems, Inc. stock logo
VAR
Varian Medical Systems
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
N/AN/AN/AN/AN/AN/AN/AN/A
Sysmex Co. stock logo
SSMXY
Sysmex
N/AN/AN/AN/AN/AN/AN/AN/A
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
3.0769 of 5 stars
4.21.00.00.02.52.51.3
Varian Medical Systems, Inc. stock logo
VAR
Varian Medical Systems
1.312 of 5 stars
0.00.00.04.40.01.72.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
2.00
HoldN/AN/A
Sysmex Co. stock logo
SSMXY
Sysmex
N/AN/AN/AN/A
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
2.46
Hold$22.2366.03% Upside
Varian Medical Systems, Inc. stock logo
VAR
Varian Medical Systems
N/AN/AN/AN/A

Current Analyst Ratings

Latest TDOC, HZNP, VAR, and SSMXY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/5/2024
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
3/6/2024
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$23.00 ➝ $17.00
2/29/2024
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$22.00
2/26/2024
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
2/26/2024
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$17.00
2/21/2024
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$22.00 ➝ $18.00
2/21/2024
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$21.00 ➝ $19.00
2/21/2024
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$26.00 ➝ $25.00
2/21/2024
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $25.00
2/21/2024
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$30.00 ➝ $25.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
$3.63B7.34$7.05 per share16.49$22.38 per share5.20
Sysmex Co. stock logo
SSMXY
Sysmex
$3.04B3.34$0.91 per share17.61$4.57 per share3.52
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
$2.60B0.87$0.79 per share16.93$14.05 per share0.95
Varian Medical Systems, Inc. stock logo
VAR
Varian Medical Systems
$3.17B5.13$5.07 per share34.94$22.92 per share7.73

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
$521.48M$1.8762.1920.553.9612.02%20.46%11.52%N/A
Sysmex Co. stock logo
SSMXY
Sysmex
$338.80M$0.5131.7925.16N/A10.25%11.15%8.23%N/A
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
-$220.37M-$1.34N/AN/AN/A-8.47%-9.22%-4.89%4/25/2024 (Confirmed)
Varian Medical Systems, Inc. stock logo
VAR
Varian Medical Systems
$269.20M$3.9160.4330.11N/A8.50%18.45%8.08%N/A

Latest TDOC, HZNP, VAR, and SSMXY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/25/2024N/A
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
-$0.47N/A+$0.47N/AN/AN/A  
2/20/2024Q4 2023
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
-$0.22-$0.17+$0.05-$0.17$670.79 million$660.50 million      
2/9/202412/31/2023
Sysmex Co. stock logo
SSMXY
Sysmex
$0.16$0.1333-$0.0267$0.20N/A$770.84 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
N/AN/AN/AN/AN/A
Sysmex Co. stock logo
SSMXY
Sysmex
$0.130.81%N/A25.66%N/A
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
N/AN/AN/AN/AN/A
Varian Medical Systems, Inc. stock logo
VAR
Varian Medical Systems
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
0.48
4.27
4.09
Sysmex Co. stock logo
SSMXY
Sysmex
0.10
3.10
2.27
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
0.66
3.54
3.47
Varian Medical Systems, Inc. stock logo
VAR
Varian Medical Systems
N/A
1.40
1.13

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
80.37%
Sysmex Co. stock logo
SSMXY
Sysmex
N/A
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
76.82%
Varian Medical Systems, Inc. stock logo
VAR
Varian Medical Systems
86.96%

Insider Ownership

CompanyInsider Ownership
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
2.20%
Sysmex Co. stock logo
SSMXY
Sysmex
N/A
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
1.63%
Varian Medical Systems, Inc. stock logo
VAR
Varian Medical Systems
0.78%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
2,115228.99 million223.96 millionOptionable
Sysmex Co. stock logo
SSMXY
Sysmex
10,522629.34 millionN/ANot Optionable
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
5,600169.31 million166.55 millionOptionable
Varian Medical Systems, Inc. stock logo
VAR
Varian Medical Systems
10,00091.84 millionN/AOptionable

TDOC, HZNP, VAR, and SSMXY Headlines

SourceHeadline
The effect of using a large language model to respond to patient messagesThe effect of using a large language model to respond to patient messages
thelancet.com - April 24 at 10:26 PM
CQ Medical™ (formerly CIVCO Radiotherapy and Qfix) is Exhibiting New Brand and Expanded Product Portfolio at ESTRO 2024CQ Medical™ (formerly CIVCO Radiotherapy and Qfix) is Exhibiting New Brand and Expanded Product Portfolio at ESTRO 2024
prnewswire.co.uk - April 24 at 12:26 PM
Healthway Cancer Care Hospital offers world-class cancer care at affordable pricesHealthway Cancer Care Hospital offers world-class cancer care at affordable prices
businessmirror.com.ph - April 24 at 12:26 PM
Q&A: Dr. Griffin Davis, Holy Cross Health’s chief clinical officer, on restructuring to offer “a better, different way of delivering care”Q&A: Dr. Griffin Davis, Holy Cross Health’s chief clinical officer, on restructuring to offer “a better, different way of delivering care”
bizjournals.com - April 22 at 1:59 PM
DelveInsight Business Research, LLP: Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsightDelveInsight Business Research, LLP: Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsight
finanznachrichten.de - April 18 at 6:35 PM
This device treats overactive bladder without drugs or surgeryThis device treats overactive bladder without drugs or surgery
medicaldesignandoutsourcing.com - April 18 at 6:35 PM
Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsightGlobal Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsight
finance.yahoo.com - April 18 at 6:35 PM
Raigmore Hospital in Scotland selects RayCareRaigmore Hospital in Scotland selects RayCare
finance.yahoo.com - April 17 at 3:14 PM
PH’s 1st dedicated cancer hospital rises in Taguig CityPH’s 1st dedicated cancer hospital rises in Taguig City
msn.com - April 15 at 10:35 PM
Robotic Radiotherapy Market Worth $1.9 billion | MarketsandMarkets™Robotic Radiotherapy Market Worth $1.9 billion | MarketsandMarkets™
finance.yahoo.com - April 15 at 5:35 PM
Robotic Radiotherapy Market Worth $1.9 billion | MarketsandMarketsRobotic Radiotherapy Market Worth $1.9 billion | MarketsandMarkets
finanznachrichten.de - April 15 at 12:34 PM
Ayala cancer hospital ready to serve 10,000 patients this yearAyala cancer hospital ready to serve 10,000 patients this year
msn.com - April 11 at 2:56 PM
Global Superficial Radiation Therapy System Industry is expected to reach US$ 58.2 Million by 2030, With A strong 3.8% CAGR | FMI | FMIGlobal Superficial Radiation Therapy System Industry is expected to reach US$ 58.2 Million by 2030, With A strong 3.8% CAGR | FMI | FMI
fmiblog.com - April 8 at 6:11 PM
Next-generation PARP inhibitor demonstrates clinical benefit in patients with homologous recombination repair-deficient breast cancerNext-generation PARP inhibitor demonstrates clinical benefit in patients with homologous recombination repair-deficient breast cancer
eurekalert.org - April 8 at 1:10 PM
The Lancet: Prostate cancer cases expected to double worldwide between 2020 and 2040, new analysis suggestsThe Lancet: Prostate cancer cases expected to double worldwide between 2020 and 2040, new analysis suggests
eurekalert.org - April 5 at 1:10 AM
Global Brachytherapy Market Set to Skyrocket, Surpassing US$ 2.1 Billion by 2032Global Brachytherapy Market Set to Skyrocket, Surpassing US$ 2.1 Billion by 2032
fmiblog.com - April 4 at 1:43 AM
New method allows miniature robots and surgical instruments to achieve precise localization inside the bodyNew method allows miniature robots and surgical instruments to achieve precise localization inside the body
msn.com - April 2 at 3:39 PM
Global Radiotherapy Device Industry Expects to Reach US$ 12,895.19 Million with 6.6% CAGR by 2033 | FMI studyGlobal Radiotherapy Device Industry Expects to Reach US$ 12,895.19 Million with 6.6% CAGR by 2033 | FMI study
fmiblog.com - April 2 at 3:39 PM
Baxter International lands key FDA clearance for infusion pumpBaxter International lands key FDA clearance for infusion pump
chicagobusiness.com - April 1 at 4:57 PM
Govt Confirms Outbreak of Infectious Disease Amid Covid-19 Fears; Gives Prevention TipsGovt Confirms Outbreak of Infectious Disease Amid Covid-19 Fears; Gives Prevention Tips
msn.com - March 28 at 8:17 PM
Robots in Healthcare Market Future Looks Bright for Market Size with Soaring ProjectionsRobots in Healthcare Market Future Looks Bright for Market Size with Soaring Projections
taiwannews.com.tw - March 28 at 8:44 AM
Radiotherapy Market Will Increase USD 32.6 Billion By 2033 And Has Guessed Around 5.9% CAGRRadiotherapy Market Will Increase USD 32.6 Billion By 2033 And Has Guessed Around 5.9% CAGR
pharmiweb.com - March 25 at 8:52 AM
Kahlert Foundation donates $2.5M to Carroll Hospital for advanced cancer-fighting technologyKahlert Foundation donates $2.5M to Carroll Hospital for advanced cancer-fighting technology
thedailyrecord.com - March 20 at 1:36 PM
Cellino Announces Ed Tekeian as Senior Vice President of EngineeringCellino Announces Ed Tekeian as Senior Vice President of Engineering
finance.yahoo.com - March 18 at 6:19 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Horizon Therapeutics Public logo

Horizon Therapeutics Public

NASDAQ:HZNP
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Sysmex logo

Sysmex

OTCMKTS:SSMXY
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, it offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; and lab assay services. Further, the company is involved in the development and sale of software for diagnostic information systems; provision of facility management, office, welfare, and genetic analysis services; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. Additionally, it researches, develops, manufactures, and sells regenerative medicine products; develops, manufactures, and sells biodevices; develops, maintains, and sells computer software; and offers blood DNA testing service. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.
Teladoc Health logo

Teladoc Health

NYSE:TDOC
Teladoc Health, Inc. provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment operates a mental health platform that provides online counseling and therapy services through website, mobile applications, phones, and text-based interactions by its licensed clinicians. The company offers its products and services under the Teladoc, Livongo, and BetterHelp brands. It serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was incorporated in 2002 and is headquartered in Purchase, New York.
Varian Medical Systems logo

Varian Medical Systems

NYSE:VAR
Varian Medical Systems, Inc. designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions worldwide. It operates through Oncology Systems and Proton Solutions segments. The Oncology Systems segment offers hardware and software products for treating cancer with radiotherapy, fixed field intensity-modulated radiation therapy, image-guided radiation therapy, volumetric modulated arc therapy, stereotactic radiosurgery, stereotactic body radiotherapy, artificial intelligence based adaptive radiotherapy, and brachytherapy, as well as quality assurance equipment. Its products include linear accelerators, brachytherapy afterloaders, treatment accessories, and quality assurance software; and information management, treatment planning, image processing, clinical knowledge exchange, patient care management, decision-making support, and practice management software. This segment serves university research and community hospitals, private and governmental institutions, healthcare agencies, physicians' offices, medical oncology practices, radiotherapy centers, and cancer care clinics. The Proton Solutions segment designs, develops, manufactures, sells, and services products and systems for delivering proton therapy for the treatment of cancer. The company has a strategic agreement with McKesson Corp. to supply treatment delivery systems and planning, services, and radiotherapy information system solutions to its U.S. Oncology Network and Vantage Oncology affiliated sites of care; and a strategic partnership with Siemens AG to represent Siemens diagnostic imaging products to radiation oncology clinics in the United States and other select markets. Varian Medical Systems, Inc. was formerly known as Varian Associates, Inc. and changed its name to Varian Medical Systems, Inc. in April 1999. The company was founded in 1948 and is headquartered in Palo Alto, California.